SCHEMBL1578052

SCHEMBL1578052

Cc1ccc(-n2cnc3c(Cl)nc(Cl)nc32)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 3/20 0.51
CFTR P13569 1/20 0.49
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
TSHR P16473 1/20 0.43
CYP2C19 P33261 1/20 0.43
GRM1 Q13255 4/20 0.41
PTGS2 P35354 2/20 0.41
P2RX7 Q99572 2/20 0.41
PTGS1 P23219 1/20 0.40
YTHDC1 Q96MU7 1/20 0.40
PI4KA P42356 1/20 0.40
PI4K2B Q8TCG2 1/20 0.40
PI4K2A Q9BTU6 1/20 0.40
PI4KB Q9UBF8 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9383398 0.84 CYP2D6 (0.58) XDHCFTRCYP2D6CYP2C9TSHR
SCHEMBL30331960 0.84 CYP2D6 (0.58) XDHCFTRCYP2D6CYP2C9TSHR
SCHEMBL30677327 0.84 XDH (0.54) XDHCFTRCYP2D6CYP2C9TSHR
SCHEMBL30677263 0.83 CFTR (0.47) XDHCFTRCYP2D6CYP2C9TSHR
SCHEMBL945799 0.82 XDH (0.55) XDHCFTRCYP2D6CYP2C9TSHR
SCHEMBL17815678 0.81 CFTR (0.60) XDHCFTRCYP2D6CYP2C9TSHR
SCHEMBL30677419 0.80 HSP90AA1 (0.38) XDHCFTRCYP2D6CYP2C9TSHR
SCHEMBL21638052 0.79 PI4KA (0.55) XDHGRM1PTGS2P2RX7PTGS1
SCHEMBL17815681 0.79 CFTR (0.79) XDHCFTRCYP2D6CYP2C9TSHR
SCHEMBL17815603 0.78 CFTR (0.56) XDHCFTRCYP2D6CYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2310391-A1 PYRAZINE SUBSTITUTED PURINES S*BIO Pte Ltd (SG) 2011-04-20 EP disclosed
WO-2009157880-A1 PYRAZINE SUBSTITUTED PURINES S*BIO PTE LTD (SG) 2009-12-30 WO disclosed
US-20070191380-A1 KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION IRM LLC (BM) 2007-08-16 US disclosed
US-7176312-B2 Kinase inhibitor scaffolds and methods for their preparation THE SCRIPPS RESEARCH INSTITUTE (US) 2007-02-13 US disclosed
EP-1578722-A2 KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION IRM LLC (BM) 2005-09-28 EP disclosed
US-20030191312-A1 Kinase inhibitor scaffolds and methods for their preparation IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) 2003-10-09 US disclosed
WO-2003031406-A2 KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION IRM LLC (BM) 2003-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191312-A1 Kinase inhibitor scaffolds and methods for their preparation MAP2K2, MAP2K1, MAP2K7 XDH 1581/4885CFTR 4885/4885CYP2D6 2366/4885
US-20070191380-A1 KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION MAP2K2, MAP2K1, MAP2K7 XDH 1581/4885CFTR 4885/4885CYP2D6 2366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.